John A. Wagner

Active 1978–2024

Also published as
John A Wagner
111
Papers
21,471
Citations
83
h-index
110
i10-index

Citations

Citations per year for John A. Wagner1979: 7 citations1980: 5 citations1981: 15 citations1982: 6 citations1983: 14 citations1984: 6 citations1985: 6 citations1986: 11 citations1987: 44 citations1988: 87 citations1989: 93 citations1990: 118 citations1991: 117 citations1992: 89 citations1993: 82 citations1994: 90 citations1995: 75 citations1996: 56 citations1997: 65 citations1998: 99 citations1999: 102 citations2000: 111 citations2001: 97 citations2002: 106 citations2003: 133 citations2004: 155 citations2005: 154 citations2006: 209 citations2007: 219 citations2008: 238 citations2009: 204 citations2010: 211 citations2011: 176 citations2012: 159 citations2013: 163 citations2014: 144 citations2015: 109 citations2016: 117 citations2017: 91 citations2018: 88 citations2019: 285 citations2020: 267 citations2021: 252 citations2022: 206 citations2023: 135 citations2024: 218 citations2025: 113 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,779 citing papers, 39.1% of this breakdownUnited Kingdom: 457 citing papers, 6.4% of this breakdownGermany: 371 citing papers, 5.2% of this breakdownCanada: 301 citing papers, 4.2% of this breakdownChina: 275 citing papers, 3.9% of this breakdownJapan: 240 citing papers, 3.4% of this breakdownFrance: 233 citing papers, 3.3% of this breakdownItaly: 225 citing papers, 3.2% of this breakdownAustralia: 209 citing papers, 2.9% of this breakdownNetherlands: 189 citing papers, 2.7% of this breakdownSwitzerland: 148 citing papers, 2.1% of this breakdownSpain: 132 citing papers, 1.9% of this breakdown
0%39.1%Other 21.7%

Fields

  • Medicine42.4%
  • Biochemistry, Genetics and Molecular Biology23%
  • Neuroscience8.9%
  • Business, Management and Accounting6.5%
  • Psychology3.6%
  • Social Sciences3.4%
  • Other12.2%

Topics

  • Adipokines, Inflammation, and Metabolic Diseases2.9%
  • Diabetes Treatment and Management2.5%
  • Adipose Tissue and Metabolism2.2%
  • Job Satisfaction and Organizational Behavior1.8%
  • Regulation of Appetite and Obesity1.5%
  • Neuroscience and Neuropharmacology Research1.3%
  • Other87.8%

Coauthors

All papers

Open in search
  1. Wearable Devices in Clinical Trials: Hype and Hypothesis

    Authors: , , - Clinical Pharmacology & Therapeutics 2017 cited by 267

  2. Retinoids regulate stem cell differentiation

    Authors: , - Journal of Cellular Physiology 2010 cited by 403

  3. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial

    Authors: , , , , , , , , , , , , , , , - Gastroenterology 2020 cited by 100

  4. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

    Authors: , , , , , , , , , , , , , , , , - Pharmaceutical Research 2006 cited by 759

  5. Organizational Behavior

    Authors: , - 2014 cited by 389

  6. Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity

    Authors: , , , , , , , , , , , , , , - Journal of Biological Chemistry 2004 cited by 1,164

  7. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

    Authors: , , , , , , , , , , , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2017 cited by 95

  8. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus

    Authors: , , , , , , - The Lancet 1998 cited by 225

  9. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea

    Authors: , , , , , , , , - Journal of Clinical Sleep Medicine 2016 cited by 76

  10. Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience

    Authors: , , , , , , , , , , , , - Clinical and Translational Science 2020 cited by 58

  11. Calcitonin gene‐related peptide: key regulator of cutaneous immunity

    Authors: , , , - Acta Physiologica 2014 cited by 95

  12. Calcitonin Gene-Related Peptide Biases Langerhans Cells toward Th2-Type Immunity

    Authors: , , , - The Journal of Immunology 2008 cited by 135

  13. Evaluation of Wearable Digital Devices in a Phase I Clinical Trial

    Authors: , , , , , , , , - Clinical and Translational Science 2019 cited by 44

  14. [ 18 F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 315

  15. Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Pharmacology & Therapeutics 2010 cited by 177

  16. Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults

    Authors: , , , , , , , , , , , , , - The Journal of Clinical Endocrinology & Metabolism 2007 cited by 162

  17. Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John F. Paolini, M. Gerard Waters, Andrew Plump - Science Translational Medicine 2012 cited by 127

  18. Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors

    Authors: , , , , , , - Clinical Pharmacology & Therapeutics 2024 cited by 16

  19. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene.

    Authors: , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1986 cited by 1,422

  20. A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies

    Authors: , , , , , , , , , , , , , , , , - Human Gene Therapy 2002 cited by 266

  21. STUDIES OF INDIVIDUALISM-COLLECTIVISM: EFFECTS ON COOPERATION IN GROUPS.

    Authors: - Academy of Management Journal 1995 cited by 1,143

  22. Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

    Authors: , , , , , , , , , , , , , , , - The Journal of Clinical Pharmacology 2006 cited by 185

  23. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness

    Authors: , , , , , , , , , , , , , - The Journal of Clinical Pharmacology 2003 cited by 144

  24. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

    Authors: , , , , , , , , , , , - Biopharmaceutics & Drug Disposition 2007 cited by 89